|
|
DAI |
|
Vaxjo ID |
362 |
|
Vaccine Adjuvant Name |
DAI |
|
Alternative Names |
ZBP1, DLM-1 |
|
Adjuvant VO ID |
VO_0005554
|
|
Description |
genetic adjuvant that induces a Th1 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
cytosolic DNA sensor, DNA-dependent activator of interferon (IFN) regulatory factors (DAI) |
|
Preparation |
DAI was produced by cloning the DAI coding sequence from mouse splenocytes into the pVAX vector |
|
Function |
activates interferon regulatory factors |
| References |
Hirvinen et al., 2016: Hirvinen M, Capasso C, Guse K, Garofalo M, Vitale A, Ahonen M, Kuryk L, Vähä-Koskela M, Hemminki A, Fortino V, Greco D, Cerullo V. Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Molecular therapy oncolytics. 2016; 3; 16002. [PubMed: 27626058].
Lladser et al., 2011: Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, Kiessling R, Ljungberg K. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Molecular therapy : the journal of the American Society of Gene Therapy. 2011; 19(3); 594-601. [PubMed: 21157438].
|
|
